India: Implications Of The Emerging Patent Litigation In India

Last Updated: 1 July 2008
Article by Manisha Singh Nair

Patent litigation, it seems, has emerged from the shadows for the time being. The nation-wide debate on the denial of patent to 'Gleevec', the cancer drug of the Swiss pharma major Novartis and also on the Patent Act being TRIPS compliant or not, the stand-off between Bajaj Auto Ltd and TVS Motors over patent on the DTS-i Engine technology, dispute over a locking mechanism involving PVC pipes, the rejection of the interlocutory application of F. Hoffman La Roche Ltd to stop Cipla Limited from manufacturing and distributing 'Erlocip', the generic version of 'Tarceva' the patented cancer drug of Roche and again a denial of patent to German pharma major Boehringer Ingelheim's product patent application for its paediatric form of the anti-AIDS drug Nevirapine under section 3(d).

This scenario has given a facelift to the existing patent jurisprudence in India but at the same time has given birth to several issues which seem amorphous in the present circumstances but, as the number of suits increase, will have profound implications.

Section 3(d), it seems, has become the bęte noire in the patent domain. There was much discussion on it world-wide after the denial of patent to Gleevec. Again we have another instance in the denial of the paediatric form of Nevirapine for not being significantly efficacious over its known form. Section 3(d) finds place in the Indian patent statute book primarily due to the 'flexibility' provided in the TRIPS Agreement in order to give room to maneuver towards safeguarding national interests. The inventing activity around existing patents and coming out with 'tweaked' products is seemingly barred by section 3(d) when it says that – the mere discovery of a new form of known substance which does not result in the enhancement of the known efficacy of that substance. The test leading towards the determination of derivatives differing significantly in properties with regard to efficacy or to distinguish between incremental innovation and frivolous changes is on the wisdom of the patent examiners. The demand of formulating a guideline or technically adequate explanations on what section 3(d) actually characterizes as un-patentable subject matter, which came up in the aftermath of denial of patent to 'Gleevec', has also gone into the closet as the government is of the view that the law is quite clear as it wants innovation to enhance the known efficacy of a substance. The government thinks that no guideline can be exhaustive and in the absence of one, it would only complicate matters. And in the event of any dissatisfaction legal remedy can always be sought. The implication of this fluid situation will definitely result in a barrage of litigation asking to adjudicate on complex technicalities of chemical and physical sciences. In the absence of a specialized IP court, is the Indian judiciary ready to take up the challenge?

Revocation of patents is provided under section 64 of the Patents Act, 1970. A patent may be revoked on a petition of any person interested or of the Central Government by the Appellate Board or on a counter-claim in a suit for infringement of the patent by the High Court on grounds as enumerated under the section. The access to patent revocation through a counter-claim is rapidly proliferating in infringement suits. Defendants when brought to the court for alleged infringing activities take the recourse of section 64 and make a counter-claim of invalidity of the impugned patent contending lack of inventive step or anticipated by what was publicly known or publicly used in India or to what was published in India or elsewhere. The counter-claim of invalidity, supposedly, has bearing from section 13 of the Patent Act, 1970. Sub-section 4 of section 13 does not warrant validity of any patent issued. The defendants use this particular statutory position to thwart off any attempt by the patentee and also the plaintiff in a typical patent infringement suit, to assert their statutory right, given under section 48 of the Patents Act, 1970, to prevent any third party from making, using, offering for sale, selling or importing the patented product or process. In the civil appeal filed by SHAND Pipe Industries against Hind Mosaic and Cement Works, involving patent on threaded PVC coupling and the locking system used in the threaded PVC pipe joint couplings with PVC pipes, the Apex Court remitted the matter for fresh consideration in accordance with law as it felt that the High Court had not analysed the scheme of the Patent Act, particularly in the context of section 13(4) read with section 48, particularly the effect of counter-claim. Section 13(4) warrants invalidity of issued patents primarily to incur no liability by the patent office for, or in connection with, any examination or investigation or any report or any proceeding thereof so as to safeguard their discretion taken in good faith. Use of no presumption of validity to bolster the counter-claim of patent invalidity is an erroneous move.

Another provision of the Patent Act, which puts patentee into quandary, is section 107. This particular provision provides for the availability of every ground which is taken up for revocation, to be taken as a defence in suits for infringement. The exclusive rights given to a patentee seems to be whittled away or diluted in the present circumstance of indiscriminately taking defence under the enumerated grounds.

Thus we see that the emerging patent litigation appears to be taking its toll on the fundamental thought behind grant of patent i.e. limited monopoly to recoup the investments made in inventing to encourage the sensitivity of innovation leading to increased economic activity.

Added to the above scenario is the new dimension given to patent litigation in the decision of Roche versus Cipla. F.Hoffman La Roche brought an infringement suit on becoming aware that Cipla Limited has launched 'Erlocip' the generic version of its patented drug, 'Tarceva'. In the application for interlocutory injunction filed by Roche, the Delhi High Court, finding that an arguable case is made out by the Plaintiff and the challenge by the defendant genuine, the Court, proceeded to decide on the question of balance of convenience while pointing out that the endeavour is only to consider whether the defendant has raised an arguable case or not in the face of an arguable case of the Plaintiff and not to make a detailed, in-depth scrutiny of the merits of the patent at the interlocutory stage. The Court, while treading with care in cases involving life saving drugs, held that the balancing in such cases would have to factor in imponderables such as the likelihood of injury to unknown parties and the potentialities of risk of denial of remedies. Thus the Court, taking the price differential in the case of a life saving drug as an important and critical factor, opined that as between the two competing public interests, that is, the public interest in granting an injunction to affirm a patent during the pendency of an infringement action, as opposed to the public interest in access for the people to a life saving drug, the balance has to be tilted in favour of the latter. However, the Court while not entitling the Plaintiff to an ad-interim injunction directed the defendant to furnish an undertaking with respect to maintaining faithful accounts of the sale of its product and filing quarterly accounts as well as duly authenticated annual statement of the sales figures in the Court. The Court said that this measure is to provide an equitable balancing order protecting the Plaintiff's interest.

This is a major implication of the emerging patent litigation. Bringing in the issue of public health and consumer access to medicines, the Court has given a new factor to be analysed while considering interim relief. Patent law has inbuilt structure like compulsory licensing to look after public health crises situations. Drug pricing is an altogether different domain which has drug pricing authorities to regulate.

The Indian patent litigation scenario is in birth throes, especially after the passing of Patent (Amendment) Act, 2005. But once these amorphous conditions sublime into concrete jurisprudence, the path is well lit for a robust patent scene in India.

© Lex Orbis 2008

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions